Terbinafine (Lamisil)

Terbinafine is an allylamine antifungal medication that has become one of the most commonly prescribed treatments for dermatophytosis (ringworm) in dogs, alongside itraconazole. Unlike the azole antifungals such as ketoconazole and itraconazole, terbinafine works through a different mechanism of action, making it a valuable alternative or complementary agent in the treatment of fungal infections. The medication is highly keratinophilic and lipophilic, meaning it concentrates well in the skin, hair follicles, and sebaceous glands where dermatophyte fungi typically reside. This property makes terbinafine particularly effective for treating superficial fungal infections of the skin, hair, and nails. The medication has also found application in treating some systemic fungal infections, either alone or in combination with azole antifungals.

The mechanism of action of terbinafine involves inhibition of the fungal enzyme squalene epoxidase, which is essential for the early stages of ergosterol biosynthesis. By blocking this enzyme, terbinafine causes accumulation of squalene (which is toxic to fungal cells) and deficiency of ergosterol (which is necessary for fungal cell membrane integrity). This dual action results in fungal cell death rather than simply inhibiting growth, making terbinafine fungicidal at therapeutic concentrations against dermatophytes. Importantly, because terbinafine targets a different enzyme than the azole antifungals, it can be used in combination with azoles for synergistic effects in treating difficult infections, and it does not have the hormonal side effects associated with some azole medications.

Terbinafine is available in several formulations suitable for treating fungal infections in dogs. Oral tablets, typically in 250 mg strength, are the primary formulation for systemic treatment of dermatophytosis and other fungal infections. Topical formulations including creams and sprays are available for localized skin infections. The oral medication is well absorbed from the gastrointestinal tract, and absorption is enhanced when given with food. After oral administration, terbinafine concentrates in the skin, achieving high levels in the stratum corneum, dermis, hair follicles, and sebaceous glands. The medication also distributes to adipose tissue and persists in skin and adipose tissue for extended periods after discontinuation, which contributes to its efficacy against fungal infections.

The safety profile of terbinafine in dogs is generally favorable, with fewer adverse effects compared to some azole antifungals. The most common side effects are gastrointestinal in nature, including decreased appetite, vomiting, and diarrhea. Because terbinafine does not significantly inhibit cytochrome P450 enzymes in the same manner as azole antifungals, it has fewer drug interactions and does not cause the hormonal disruptions (such as decreased cortisol or testosterone production) that can occur with ketoconazole. Hepatotoxicity is possible but appears to be less common than with azole antifungals. Veterinary supervision is still essential for safe and effective use, with appropriate monitoring during treatment.

Terbinafine is primarily indicated for the treatment of dermatophytosis, commonly known as ringworm, in dogs. Dermatophyte infections are caused by fungi that invade keratinized tissues including the skin, hair, and nails. The most common dermatophytes affecting dogs are Microsporum canis and Trichophyton mentagrophytes. Terbinafine, along with itraconazole, is now considered one of the most effective systemic treatments for canine dermatophytosis, having largely supplanted griseofulvin as the preferred therapy. The medication's ability to concentrate in the skin and hair follicles at high levels makes it particularly well-suited for treating these superficial fungal infections. Clinical signs of dermatophytosis in dogs typically include circular areas of hair loss, scaling, crusting, and sometimes inflammation of the skin.

Beyond its primary indication for dermatophytosis, terbinafine has demonstrated activity against several organisms causing systemic fungal infections in dogs. The medication has been used as part of combination therapy for blastomycosis, particularly in cases that are not responding adequately to azole antifungal monotherapy. Adding terbinafine to fluconazole or itraconazole therapy can improve treatment outcomes in approximately half of dogs with inadequate response to azole therapy alone. Similarly, terbinafine may be used in combination with azoles for treatment of histoplasmosis, cryptococcosis, and other systemic mycoses when first-line therapy proves insufficient.

Sporotrichosis, a fungal infection caused by Sporothrix schenckii that typically enters through skin wounds, is another indication where terbinafine has shown efficacy. Terbinafine has been used as a sole agent or in combination with itraconazole for treating sporotrichosis in dogs. The medication may also have a role in treating gastrointestinal pythiosis, a fungal-like infection caused by Pythium insidiosum, typically as part of combination therapy with azole antifungals. While Malassezia (yeast) infections are common in dogs, terbinafine is generally considered less effective for these compared to azole antifungals and is not typically a first-choice for Malassezia dermatitis or otitis.

The selection of terbinafine for treating fungal infections depends on various factors including the type of organism causing infection, the severity and location of disease, prior treatments, and patient factors. For dermatophytosis, both terbinafine and itraconazole are considered excellent first-line options, and the choice between them may depend on factors such as cost, dosing convenience, and individual patient tolerability. Terbinafine's lack of hormonal effects and fewer drug interactions make it advantageous in some situations. For systemic mycoses, terbinafine is most commonly used as add-on therapy when azole monotherapy is inadequate, rather than as a sole agent. The veterinarian will consider all relevant factors when determining the most appropriate antifungal treatment plan for each patient.

The dosing of terbinafine in dogs must be determined by the veterinarian based on the specific condition being treated, the dog's body weight, and individual patient factors. Accurate weight measurement is essential for proper dosing, as terbinafine is prescribed on a milligram per kilogram basis and inappropriate dosing can result in treatment failure or increased risk of adverse effects. Dosing protocols for terbinafine in dogs may vary depending on the source, and the veterinarian will select an appropriate regimen based on current evidence and clinical judgment.

For treatment of dermatophytosis in dogs, common dosing protocols involve administration of 20-40 mg per kilogram of body weight once daily. Some sources recommend doses at the lower end of this range (around 20-30 mg per kilogram), while others have used higher doses. A commonly cited dose is 30-40 mg per kilogram once daily. It is worth noting that terbinafine pharmacokinetics differ between dogs and cats, with the medication not accumulating in dog skin as well as it does in cat or human skin. This has led to recommendations for higher doses in dogs compared to cats. The veterinarian will determine the appropriate dose for the individual patient based on current knowledge and clinical considerations.

The duration of terbinafine treatment for dermatophytosis typically extends for several weeks, continuing until the infection is confirmed to be cleared through negative fungal cultures. Treatment duration commonly ranges from four to eight weeks, though it may be longer depending on the extent and location of infection and the individual patient's response. Nail infections typically require longer treatment than skin infections due to the slower turnover of nail tissue. Treatment should not be discontinued simply because clinical signs have resolved, as the fungal organism may still be present. The veterinarian will schedule follow-up appointments including fungal cultures to determine when treatment can be safely stopped.

Proper administration of oral terbinafine helps optimize absorption and minimize gastrointestinal side effects. The medication should be given with food, which enhances absorption and may reduce the likelihood of stomach upset. Tablets can be given directly by mouth or hidden in food. For dogs requiring doses that do not match available tablet sizes, tablets may need to be split or compounded formulations may be obtained from a compounding pharmacy. The medication is typically administered once daily, though some protocols may divide the daily dose into multiple administrations.

If a dose of terbinafine is missed, it should generally be given as soon as remembered. If it is close to the time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Doses should not be doubled to make up for missed doses. Consistent daily administration at approximately the same time each day helps maintain effective drug levels in the skin where fungal infections reside. If multiple doses are missed or if there is confusion about the dosing schedule, the owner should contact the veterinarian for guidance.

Completing the full prescribed course of terbinafine treatment is essential for achieving cure and preventing recurrence of fungal infection. Because dermatophyte infections can appear clinically resolved before the organism is completely eliminated, stopping treatment prematurely based on clinical improvement alone frequently leads to relapse. Treatment should continue until fungal cultures confirm that the infection has been eradicated. Owner compliance with the full treatment course is critical for successful outcomes.

Terbinafine is generally well tolerated by dogs, with a favorable safety profile compared to some other antifungal medications, particularly the azole antifungals. Most dogs complete their treatment course without experiencing significant adverse effects. However, as with any medication, side effects can occur, and owners should be aware of potential signs to watch for during treatment. Regular veterinary follow-up allows for monitoring of treatment response and early detection of any adverse effects that may develop.

The most commonly observed side effects of terbinafine in dogs are gastrointestinal in nature. Decreased appetite, nausea, vomiting, and diarrhea have been reported in dogs receiving the medication. These effects are often mild and may resolve spontaneously or with administration of the medication with food. If gastrointestinal signs are persistent or severe, the veterinarian should be contacted, as dose adjustment or alternative treatment may be needed. Some dogs may experience mild diarrhea that does not significantly impact their overall wellbeing or require treatment discontinuation.

Some dogs have been reported to exhibit panting while receiving terbinafine, though the mechanism for this effect is not well understood. Additionally, temporary eye membrane inflammation (conjunctivitis) has been noted in some dogs during terbinafine treatment. These effects typically resolve when the medication is discontinued. If excessive panting, eye redness, or discharge develops during treatment, the owner should inform the veterinarian, who can determine whether these signs warrant modification of the treatment plan.

Hepatotoxicity, while less common with terbinafine than with some azole antifungals, remains a potential concern. Elevated liver enzymes may be detected on blood testing, and clinical signs of liver problems could include vomiting, decreased appetite, lethargy, jaundice (yellowing of the gums or whites of the eyes), or changes in stool or urine color. The veterinarian may recommend baseline liver function testing before starting treatment and periodic monitoring during extended treatment courses. If significant liver enzyme elevations or clinical signs of hepatic disease develop, the medication may need to be discontinued.

Other potential side effects are relatively uncommon. Allergic reactions, while rare, can occur with any medication and may manifest as hives, facial swelling, or difficulty breathing, requiring immediate veterinary attention. Skin reactions have been reported in humans taking terbinafine. Because terbinafine does not have the same cytochrome P450 inhibitory effects as azole antifungals, it does not cause the hormonal disruptions (decreased cortisol, testosterone) that can occur with ketoconazole. If any unusual symptoms develop during terbinafine treatment, owners should contact their veterinarian to determine whether dose adjustment, discontinuation, or other intervention is needed.

Terbinafine should not be used in dogs with known hypersensitivity or allergic reactions to the medication. Dogs that have previously experienced adverse reactions to terbinafine should not receive the drug again, as subsequent exposures could result in similar or more severe reactions. Any history of medication allergies should be communicated to the veterinarian so that appropriate alternatives can be considered. Allergic reactions may manifest as skin reactions, gastrointestinal upset, or more severe systemic signs.

Significant liver disease is a relative contraindication for terbinafine use in dogs. While terbinafine is generally considered to have lower hepatotoxic potential than azole antifungals, the medication is metabolized by the liver and can potentially cause liver enzyme elevations. Dogs with pre-existing hepatic dysfunction may have altered drug metabolism, and additional hepatic stress from the medication could worsen their condition. Dogs with known liver disease should receive terbinafine only if the benefits clearly outweigh the risks and if the veterinarian determines it is appropriate after careful consideration. More frequent liver function monitoring would be warranted in such cases.

Terbinafine should not be used in pregnant dogs due to potential risks to developing fetuses. While specific teratogenicity data in dogs is limited, the medication is not recommended during pregnancy as a precautionary measure. Similarly, terbinafine should be avoided in nursing dogs, as the medication is excreted in milk and could affect nursing puppies. Dogs intended for breeding should complete their antifungal treatment before breeding is attempted. The veterinarian can provide guidance on appropriate waiting periods between treatment completion and breeding.

Other conditions that may warrant caution with terbinafine use include significant kidney impairment, as the medication is partially eliminated through the kidneys. While dose adjustment is not typically required for mild to moderate renal impairment, severe kidney disease may affect drug elimination. Dogs receiving medications that interact significantly with terbinafine should have the potential for interaction carefully evaluated. Severely debilitated or immunocompromised dogs may require special consideration and monitoring during treatment. The veterinarian will evaluate the individual patient's health status and medical history to determine whether terbinafine is appropriate or whether alternative treatment should be considered.

Terbinafine generally has fewer drug interactions than azole antifungals, as it does not inhibit cytochrome P450 enzymes as potently as ketoconazole or itraconazole. However, some interactions do exist, and informing the veterinarian of all medications, supplements, and products the dog is receiving is important before starting terbinafine therapy. Understanding potential interactions helps ensure safe and effective treatment.

Terbinafine is metabolized by several cytochrome P450 enzymes, and medications that induce or inhibit these enzymes can affect terbinafine blood levels. Drugs that are removed from the body via similar metabolic pathways may have their levels affected when used concurrently with terbinafine. These potentially affected medications include selegiline (an MAO inhibitor used for canine cognitive dysfunction), amitraz (found in some tick prevention products), beta-blockers (heart medications), tricyclic antidepressants (such as clomipramine and amitriptyline), trazodone, narcotic pain relievers, and selective serotonin reuptake inhibitors (such as fluoxetine). When these medications are used with terbinafine, they may have prolonged or enhanced effects due to altered metabolism.

Terbinafine may affect the blood levels of cyclosporine, an immunosuppressant used in dogs for immune-mediated diseases and allergies. Specifically, terbinafine may facilitate the removal of cyclosporine from the body, potentially making cyclosporine less effective. If a dog is receiving cyclosporine and requires antifungal therapy, the veterinarian may need to monitor cyclosporine levels and adjust the dose accordingly. Alternatively, a different antifungal may be selected.

Unlike azole antifungals, terbinafine does not have significant interactions with medications affected by gastric pH. Antacids, H2 blockers, and proton pump inhibitors can be used concurrently without significantly affecting terbinafine absorption. This is an advantage of terbinafine over itraconazole and ketoconazole in dogs that require acid-suppressing medications for other conditions.

The veterinarian will review all concurrent medications and assess potential interactions before prescribing terbinafine. If interactions are identified, the treatment plan may be modified through dose adjustments, timing changes, enhanced monitoring, or selection of alternative medications. Signs of drug interactions may include unexpected changes in the dog's response to medications, development of new symptoms, or changes in disease control. Any concerns about potential interactions should be discussed with the veterinarian.

Several general precautions should be observed when terbinafine is prescribed for dogs to ensure safe and effective treatment. Accurate weight measurement is essential for proper dosing, and the medication should be administered with food to enhance absorption and minimize gastrointestinal side effects. Regular follow-up appointments allow the veterinarian to monitor treatment response and assess for adverse effects. Owners should administer the medication exactly as prescribed and should not adjust the dose or discontinue treatment without veterinary guidance.

Liver function monitoring may be advisable during terbinafine therapy, particularly for extended treatment courses. While terbinafine is generally considered to have lower hepatotoxic potential than azole antifungals, it can cause liver enzyme elevations in some patients. Baseline liver function testing before starting treatment provides a reference point for comparison, and periodic monitoring during treatment (such as every four to six weeks for extended courses) can help detect any hepatic effects early. Dogs with pre-existing liver disease or those receiving other potentially hepatotoxic medications warrant more careful monitoring.

While terbinafine does not have the extensive drug interaction potential of azole antifungals, caution is still warranted when the medication is used concurrently with other drugs. Medications metabolized by similar pathways may have altered effects, and the veterinarian should review all concurrent medications before starting terbinafine. Particular attention should be paid to concurrent use of psychoactive medications, cardiac drugs, and immunosuppressants like cyclosporine.

Breed-specific considerations for terbinafine are not well documented, but general principles of medication use in dogs apply. Dogs with the MDR1 (ABCB1) gene mutation found in many herding breeds are not specifically known to have altered terbinafine handling, but as with any medication, awareness of this genetic variant is relevant. Terbinafine does not appear on standard lists of drugs of particular concern for MDR1-mutant dogs, but caution is always appropriate when treating dogs known or suspected to carry this mutation.

Special populations of dogs require consideration. Geriatric dogs may have decreased liver and kidney function that could affect drug handling. Very young puppies have immature organ function and may require careful dosing. Pregnant and nursing dogs should not receive terbinafine. Dogs with chronic conditions requiring multiple medications need review for potential interactions. Working and performance dogs may need consideration of how treatment schedules fit with their activities. The veterinarian will consider all patient factors when developing an appropriate treatment plan.

Proper storage of terbinafine tablets helps maintain the medication's stability and effectiveness. Tablets should be stored at room temperature, typically between 68°F and 77°F (20°C and 25°C), protected from light. The medication should be kept in its original container with the lid tightly closed to protect from moisture. Storage locations should be away from heat sources such as stoves, radiators, or areas receiving direct sunlight. Bathrooms are often not ideal storage locations due to humidity from showers and baths. A cool, dry cabinet or drawer provides suitable storage conditions. The expiration date should be checked before use, and expired medication should not be administered.

Topical terbinafine products such as creams and sprays have their own storage requirements. These formulations should typically be stored at room temperature and protected from extreme heat or cold. Containers should be kept tightly closed when not in use to prevent drying or contamination. Topical products should be discarded if they appear discolored, have an unusual texture, or show other signs of degradation. Expiration dates should be observed for both oral and topical formulations.

Safe storage of terbinafine in households with pets and children is important. Oral tablets should be stored in a secure location that children and pets cannot access, such as a high cabinet with a secure closure or a locked medicine cabinet. Child-resistant containers should be used and properly secured after each use. When dispensing doses, only the amount needed should be removed, and the container should be immediately returned to secure storage. Any dropped or spilled tablets should be retrieved promptly. Accidental ingestion of multiple doses could cause gastrointestinal upset and potentially other adverse effects.

Proper disposal of unused or expired terbinafine protects the environment and prevents accidental exposure. Medications should not be flushed down the toilet or poured down drains. Many communities have drug take-back programs that accept unused medications for safe disposal; veterinary clinics may also participate. If no take-back option is available, the FDA recommends mixing the medication with an undesirable substance such as coffee grounds or cat litter, placing it in a sealed container, and disposing of it in household trash with personal information removed from the label. Questions about proper disposal can be directed to the veterinarian or pharmacist.

Most dog breeds tolerate terbinafine well when the medication is used at appropriate doses with proper monitoring. No specific breed-related contraindications or sensitivities have been definitively established for terbinafine in dogs. The medication's favorable safety profile and lack of hormonal effects make it suitable for use across various breeds. However, individual variation in drug tolerance exists, and veterinarians consider breed along with other patient factors when developing treatment plans.

Dogs with the MDR1 (ABCB1) gene mutation, found in many herding breeds, do not appear to have specific sensitivity to terbinafine based on current knowledge. Terbinafine is not on standard lists of drugs that are problematic for MDR1-mutant dogs in the way that ivermectin at higher doses or certain other medications are. However, as with any medication, awareness of this genetic variant is relevant when treating dogs of affected breeds, which include Collies, Australian Shepherds, Shetland Sheepdogs, Old English Sheepdogs, Border Collies, Long-haired Whippets, Silken Windhounds, and mixed breeds with herding dog heritage. The veterinarian may still exercise appropriate caution when prescribing any medication to dogs known or suspected to carry the MDR1 mutation.

Certain breeds may be more commonly affected by dermatophytosis and therefore more likely to receive terbinafine therapy. Yorkshire Terriers and Persian-mix dogs have been reported to have higher rates of dermatophyte infection in some studies. Dogs with compromised immune systems from any cause may be more susceptible to fungal infections and may require extended treatment courses. Breeds predisposed to conditions that can compromise immunity or skin health may benefit from close monitoring during treatment.

Size considerations are important when dosing terbinafine, given the wide range of body weights among dog breeds. Toy breeds weighing only a few pounds require careful dose calculation, and the available 250 mg tablet size may need to be divided or compounded formulations obtained for accurate dosing in very small dogs. Giant breeds require larger amounts of medication, which has implications for treatment cost. Age-related considerations apply across all breeds. Geriatric dogs may have decreased liver and kidney function affecting drug metabolism and elimination. Very young puppies have immature organ function. The veterinarian considers age, breed, size, and overall health status when determining the appropriate treatment approach.

Terbinafine is part of a group of antifungal medications used to treat fungal infections in dogs, each with different mechanisms of action, spectra of activity, and safety profiles. Itraconazole (Sporanox) is a triazole antifungal that is considered equally effective to terbinafine for treating dermatophytosis in dogs. Itraconazole has a broader spectrum of activity that includes systemic fungal infections such as blastomycosis, histoplasmosis, and cryptococcosis. The choice between terbinafine and itraconazole for ringworm often depends on factors such as cost, dosing convenience, and individual patient considerations. Both are considered first-line options for canine dermatophytosis.

Griseofulvin is an older antifungal that was the historical standard for treating dermatophytosis before terbinafine and itraconazole became widely used. While still effective for ringworm, griseofulvin has largely been supplanted by the newer agents due to their improved safety profiles and, in some cases, better efficacy. Griseofulvin has no activity against systemic fungal infections or Malassezia yeast. Ketoconazole is another azole antifungal that can treat dermatophytosis, though it is generally considered less effective than itraconazole and has more potential for adverse effects including hepatotoxicity and hormonal disruption.

Fluconazole is a triazole antifungal primarily used for systemic fungal infections, particularly cryptococcosis and coccidioidomycosis (Valley Fever), due to its excellent penetration into the central nervous system. However, fluconazole has relatively poor activity against dermatophytes and is not typically used for ringworm. For serious systemic mycoses, terbinafine may be used in combination with fluconazole or itraconazole to enhance treatment efficacy, particularly in cases that are not responding adequately to azole monotherapy.

Topical antifungal products are often used alongside systemic therapy for dermatophytosis. Lime sulfur dips, miconazole-chlorhexidine shampoos, and enilconazole rinses help reduce environmental contamination with fungal spores and can speed resolution of skin lesions. Topical terbinafine products (cream, spray) may be used for localized fungal infections, though systemic therapy is usually needed for more extensive infections. The veterinarian may recommend a combination of systemic and topical treatment for optimal outcomes in managing dermatophytosis. Any changes to antifungal therapy should be made under veterinary guidance, as different medications have different dosing requirements and monitoring needs.